Study | BMSC (n) | Control (n) | Cell dose | Injection time | Baseline LVEF (%) | Follow-up |
---|---|---|---|---|---|---|
Cao et al.[19] | 41 | 45 | 5 × 108 | 7 days | 38.8 | 6 mo |
Chang et al. [20] | 20 | 20 | 1.5 × 109 | 3 days | 52.9 | 6 mo |
Grajeck et al.[21] | 31 | 14 | 0.41 × 109 | 4–5 days | 55.5 | 6 mo |
Herbots et al.[2] | 33 | 34 | 3.04 × 108 | 4–7 days | 55.5 | 4 mo |
Huikuri et al.[3] | 36 | 36 | 4.02 × 108 | 2.5 days | 56.5 | 6 mo |
Meluzin et al.[22] | 20 | 20 | 1 × 108 | 5–9 days | 40.5 | 6 mo |
Penicka et al.[23] | 17 | 10 | 26.4 × 108 | 4–11 days | 39 | 4 mo |
Piepoli et al.[24] | 19 | 19 | 2.48 × 108 | 4 days | 38.7 | 6 mo |
Plewka et al.[25]) | 40 | 20 | 1.44 × 108 | 7 days | 34 | 6 mo |
Schachinger et al.[4] | 101 | 103 | 2.36 × 108 | 3–6 days | 47.1 | 4 mo |
Suarez de Lezo et al. [26] | 10 | 10 | 9 × 108 | 7 days | 38 | 3 mo |
Tendera et al.[27] | 80 | 40 | 1.78 × 108 | 7 days | 37 | 6 mo |
Traverse et al.[5] | 30 | 10 | 1.5 × 108 | 4.5 days | 38 | 6 mo |
Traverse et al.[6] | 58 | 29 | 1.5 × 108 | 14–21 days | 47 | 6 mo |
Wohrle et al.[7] | 29 | 13 | 3.81 × 108 | 5–7 days | 59.6 | 6 mo |
Wollert et al.[28] | 30 | 30 | 24.6 × 108 | 4.8 days | 50.7 | 6 mo |
Yao et al.[29] | 12 | 12 | 2.0 × 108 | 3–7 days | 32.4 | 6 mo |